Denali Therapeutics Inc. (DNLI) PT Raised to $105 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Price: $18.41 -1.34%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
H.C. Wainwright analyst Andrew Fein raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $105.00 (from $95.00) while maintaining a Buy rating.
You May Also Be Interested In
- Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
- Deckers Outdoor (DECK) PT Lowered to $100 at Williams Trading
- AppFolio (APPF) PT Raised to $250 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
